How CAR-Ts Are Changing The Lifecycle Paradigm For ATMPs
Executive Summary
CAR T-cell therapies have resulted in the industry and regulators exploring unconventional approaches to collecting real-world safety and efficacy data from existing registries. Can this approach also work for other types of cell and gene therapy products in the future? Delegates at a conference in London explored the topic.
You may also be interested in...
How To Improve Post-Approval Evidence Generation
A new scientific paper explains how companies can improve their post-licensing evidence generation plans by seeking scientific advice from EU regulators and health technology bodies at appropriate times during the drug development process.
Loud And Clear: EMA Gets Message On Advancing Reg Science
The European Medicines Agency has identified key areas where stakeholders want to see it deliver a real change over the next five years.
EMA Defines Actions For Using CAR-T Registries For Regulatory Evaluation
A multi-stakeholder EU workshop has helped identify how patient registries can support the benefit-risk evaluation of CAR-T cell therapies, given the challenges posed by these products, not least the need for the long-term follow up of treated patients.